Traders should monitor for FDA communication outcomes in Q2 2026, which will determine whether ARD-101 development can resume. The cardiac safety signal introduces significant regulatory and clinical risk, potentially impacting valuation despite strong preclinical and early clinical data.
Price Chart
Executive Summary
Aardvark Therapeutics has voluntarily paused its Phase 3 trials for ARD-101 in Prader-Willi Syndrome and related obesity programs due to reversible cardiac QRS prolongation observed in healthy volunteers, though no serious adverse events were reported. The company maintains a strong cash position of $110.0 million, sufficient to fund operations into Q2 2027, while it engages with the FDA to determine next steps, with further guidance expected in Q2 2026.
Key Financial Metrics
Key Facts
- Voluntary pause of Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome due to reversible QRS prolongation in healthy volunteers.
- ARD-201 obesity trials (POWER and STRENGTH) also paused pending FDA discussions.
- Two of eight healthy volunteers at 1,600 mg BID showed >25% increase in QRS duration; one case at 800 mg BID in follow-on cohort.
- No serious adverse events or cardiac symptoms; all QRS changes were reversible upon discontinuation.
- Exposure-response relationship identified: higher plasma concentrations linked to QRS prolongation.
- Cash, cash equivalents, and short-term investments totaled $110.0 million as of December 31, 2025, up from $73.7 million in 2024.
- R&D expenses increased to $48.9 million in 2025 from $17.4 million in 2024.
- Net loss for 2025 was $57.6 million vs. $20.6 million in 2024.
- Company expects to provide further program guidance in Q2 2026.
Financial Impact
Increased R&D spending by $31.6 million year-over-year, leading to a tripling of net loss to $57.6 million for the year; cash runway extended to Q2 2027.
Risk Factors
- Regulatory delay or rejection due to cardiac safety concerns (QRS prolongation).
- Clinical trial restart uncertainty may lead to extended development timelines or trial redesign.
- Increased cash burn may pressure future financing needs if trials require modifications or expansion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260833 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | Press Release | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 8, 2026 18d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Oct 8, 2026 18d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.08 (−70.33%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.08 (+76.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers